Tempus
VC Fund
Chicago, United States
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions todeliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Tempus invests in
Stages Tempus invests in
Countries Tempus invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jonathan Ozeran
|
|||
Andrew Polovin
|
|||
Kimberly Yeatts
|
|||
Martin Stumpe
|
|||
| See all 9 contacts → | |||
Investment Focus
Industry
- Biotechnology 3 (60%)
- Genetics 2 (40%)
- Health Care 2 (40%)
- B2B 1 (20%)
- Travel 1 (20%)
Stage
- Series A 1 (20%)
- Series C 1 (20%)
- Funding Round 1 (20%)
- Post-IPO Equity 1 (20%)
Country
- United States 2 (40%)
- Singapore 1 (20%)
- United Kingdom 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Eric Lefkofsky
Founder and CEO
|
Founder and CEO | Total investments: 84 | Find email | |
|
Jonathan Ozeran
Director of Product
|
Director of Product | Total investments: 1 | Find email | |
|
Andrew Polovin
General Counsel
|
General Counsel | Total investments: 0 | Find email | |
|
Kimberly Yeatts
Vice President of Clinical Lab Operations
|
Vice President of Clinical Lab Operations | Total investments: 0 | Find email | |
|
Martin Stumpe
Chief of AI
|
Chief of AI | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Personalis
|
Personalis combines both the technology of sequencing and interpretation, with an extensive history of peer-reviewed publication and commercial success. It is providing an extensive molecular view of a patient’s tumor and characterizes its interplay with the immune system. It aids in the development of safer, effective precision cancer therapies,immunotherapies, and personalized medicines. | $36.1M / Post-IPO Equity / Aug 16, 2024 | |
Akrivia Health
|
Akrivia Health provides real-world data for evidence generation, clinical trial optimization, and molecular characterization for mental health and dementia. It also provides assistance in the processes of early-stage drug discovery, market analysis, clinical trial revenue management, and more. | $5.9M / Series A / Jun 20, 2021 | |
8Trip
|
8Trip, a China-based online travel service which connects suppliers with sellers. Currently, 8Trip covers the markets of Wuxi, Nanjing, and Anhui in China, and is planning to enter the Shanghai market next year. The company has partnerships with about 1,000 travel agencies and more than 4,000 service outlets. 8Trip was founded in December 2011under the company name Octopus Online Tourism Development, with headquarters in Suzhou. | $85M / Series C / Apr 09, 2018 | |
Exicure
|
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $20M / Sep 27, 2017 | |
|
Exicure
|
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $14.8M / Oct 21, 2015 |
Co-Investors
AbbVie Biotech Ventures
1 deal together
Ant Group
1 deal together
CCB International
1 deal together
Katalyst Securities
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Tempus invest in?
Tempus invests primarily in Biotechnology, Genetics and Health Care startups, most often at Series A and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Tempus?
Public channels for Tempus include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tempus?
The team at Tempus includes Eric Lefkofsky (Founder and CEO), Jonathan Ozeran (Director of Product) and Andrew Polovin (General Counsel), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
